261 related articles for article (PubMed ID: 17912749)
1. Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells.
Argilés JM; Figueras M; Ametller E; Fuster G; Olivan M; de Oliveira CC; López-Soriano FJ; Isfort RJ; Busquets S
Muscle Nerve; 2008 Feb; 37(2):190-5. PubMed ID: 17912749
[TBL] [Abstract][Full Text] [Related]
2. Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma.
Carbó N; Costelli P; Busquets S; López-Soriano J; López-Soriano FJ; Baccino FM; Argilés JM
Int J Mol Med; 2004 Oct; 14(4):719-23. PubMed ID: 15375607
[TBL] [Abstract][Full Text] [Related]
3. Patterns of gene expression in muscle and fat in tumor-bearing rats: effects of CRF2R agonist on cachexia.
Argilés JM; Fontes-Oliveira CC; Fuster G; Ametller E; Figueras M; Olivan M; Lopez-Soriano FJ; Qu X; Demuth J; Stevens P; Varbanov A; Wang F; Isfort RJ; Busquets S
Muscle Nerve; 2010 Dec; 42(6):936-49. PubMed ID: 21104868
[TBL] [Abstract][Full Text] [Related]
4. Effects of a CRF2R agonist and exercise on mdx and wildtype skeletal muscle.
Hall JE; Kaczor JJ; Hettinga BP; Isfort RJ; Tarnopolsky MA
Muscle Nerve; 2007 Sep; 36(3):336-41. PubMed ID: 17503504
[TBL] [Abstract][Full Text] [Related]
5. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
6. Effects of the PPARgamma agonist GW1929 on muscle wasting in tumour-bearing mice.
Moore-Carrasco R; Figueras M; Ametller E; López-Soriano FJ; Argilés JM; Busquets S
Oncol Rep; 2008 Jan; 19(1):253-6. PubMed ID: 18097603
[TBL] [Abstract][Full Text] [Related]
7. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice.
Tanaka K; Urata N; Mikami M; Ogasawara M; Matsunaga T; Terashima N; Suzuki H
Inflamm Res; 2007 Jan; 56(1):17-23. PubMed ID: 17334666
[TBL] [Abstract][Full Text] [Related]
8. Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions.
Hinkle RT; Donnelly E; Cody DB; Samuelsson S; Lange JS; Bauer MB; Tarnopolsky M; Sheldon RJ; Coste SC; Tobar E; Stenzel-Poore MP; Isfort RJ
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E889-98. PubMed ID: 12959937
[TBL] [Abstract][Full Text] [Related]
9. Corticotropin-releasing factor 2 receptor localization in skeletal muscle.
Samuelsson S; Lange JS; Hinkle RT; Tarnopolsky M; Isfort RJ
J Histochem Cytochem; 2004 Jul; 52(7):967-77. PubMed ID: 15208363
[TBL] [Abstract][Full Text] [Related]
10. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
Busquets S; Figueras MT; Fuster G; Almendro V; Moore-Carrasco R; Ametller E; Argilés JM; López-Soriano FJ
Cancer Res; 2004 Sep; 64(18):6725-31. PubMed ID: 15374990
[TBL] [Abstract][Full Text] [Related]
11. Conjugated linoleic acid preserves gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma.
Graves E; Hitt A; Pariza MW; Cook ME; McCarthy DO
Res Nurs Health; 2005 Feb; 28(1):48-55. PubMed ID: 15625711
[TBL] [Abstract][Full Text] [Related]
12. Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy.
Isfort RJ; Wang F; Tscheiner M; Donnelly E; Bauer MB; Lefever F; Hinkle RT; Mazur AW
J Med Chem; 2005 Jan; 48(1):262-5. PubMed ID: 15634020
[TBL] [Abstract][Full Text] [Related]
13. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice.
Nicholson JR; Kohler G; Schaerer F; Senn C; Weyermann P; Hofbauer KG
J Pharmacol Exp Ther; 2006 May; 317(2):771-7. PubMed ID: 16436498
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats.
Figueras M; Busquets S; Carbó N; Barreiro E; Almendro V; Argilés JM; López-Soriano FJ
FEBS Lett; 2004 Jul; 569(1-3):201-6. PubMed ID: 15225634
[TBL] [Abstract][Full Text] [Related]
15. Luteolin reduces cancer‑induced skeletal and cardiac muscle atrophy in a Lewis lung cancer mouse model.
Chen T; Li B; Xu Y; Meng S; Wang Y; Jiang Y
Oncol Rep; 2018 Aug; 40(2):1129-1137. PubMed ID: 29845270
[TBL] [Abstract][Full Text] [Related]
16. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
Toledo M; Busquets S; Penna F; Zhou X; Marmonti E; Betancourt A; Massa D; López-Soriano FJ; Han HQ; Argilés JM
Int J Cancer; 2016 Apr; 138(8):2021-9. PubMed ID: 26595367
[TBL] [Abstract][Full Text] [Related]
17. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI.
Kawamura I; Lacey E; Inami M; Nishigaki F; Naoe Y; Tsujimoto S; Manda T; Goto T
Anticancer Res; 1999; 19(5B):4091-7. PubMed ID: 10628359
[TBL] [Abstract][Full Text] [Related]
18. Provision of rhIGF-I/IGFBP-3 complex attenuated development of cancer cachexia in an experimental tumor model.
Wang W; Iresjö BM; Karlsson L; Svanberg E
Clin Nutr; 2000 Apr; 19(2):127-32. PubMed ID: 10867731
[TBL] [Abstract][Full Text] [Related]
19. Multiple organ failure of tumor-bearing rabbits in cancer cachexia is caused by apoptosis of normal organ cells.
Fukuda T; Sumi T; Nobeyama H; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Oncol; 2009 Jan; 34(1):61-7. PubMed ID: 19082478
[TBL] [Abstract][Full Text] [Related]
20. DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia?
van Royen M; Carbó N; Busquets S; Alvarez B; Quinn LS; López-Soriano FJ; Argilés JM
Biochem Biophys Res Commun; 2000 Apr; 270(2):533-7. PubMed ID: 10753659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
